Azithromycin-13C-d3 is intended for use as an internal standard for the quantification of azithromycin by GC- or LC-MS. Azithromycin is a macrolide antibiotic.1 It is active against S. pneumoniae, S. aureus, N. gonorrhoeae, M. pneumoniae, H. pylori, C. trachomatis, and H. influenzae in vitro (MIC90s = <0.01-2 mg/L). Azithromycin increases survival in mouse models of intraperitoneal S. pyogenes, S. pneumoniae, E. faecalis, or H. influenzae infection (ED50s = 0.78, 8.7, 12.7, and 30.3 mg/kg, respectively).2 It also decreases plasma levels of IL-6, TNF-α, and IL-1β and increases survival in mouse model of LPS-induced sepsis when administered at a dose of 100 mg/kg.3 Formulations containing azithromycin have been used in the treatment of a variety of bacterial infections.
1.Kanatani, M.S., and Guglielmo, B.J.The new macrolides. Azithromycin and clarithromycinWestern J. Med.160(1)31-37(1994) 2.Girard, D., Finegan, S.M., Dunne, M.W., et al.Enhanced efficacy of single-dose versus multi-dose azithromycin regimens in preclinical infection modelsJ. Antimicrob. Chemother.56(2)365-371(2005) 3.Patel, A., Joseph, J., Periasamy, H., et al.Azithromycin in combination with ceftriaxone reduces systemic inflammation and provides survival benefit in a murine model of polymicrobial sepsisAntimicrob. Agents Chemother.62(9)e00752-00718(2018)